Lipid-lowering drug introduced by Eddingpharm was approved in Hong Kong, China

On March 29, Eddingpharm announced that the new drug marketing application of Eicosapentaenoic acid ethyl ester capsules (trade name Vascepa) for reducing the risk of cardiovascular events has been approved in Hong Kong, China.

Vascepa is a single-molecule prescription drug containing the highly purified active ingredient ethyl eicosapentaenoate (IPE, a unique form of eicosapentaenoic acid)

Vascepa was first marketed in the U.

This time, Eddingpharm's submission of Vascepa's new drug marketing application in Hong Kong, China is based on the results of the REDUCE-IT study and the approval results of Vascepa in the United States and Canada

The main findings of the REDUCE-IT study were published in the New England Journal of Medicine in November 2018

It is reported that China's National Medical Products Administration (NMPA) has also accepted Vascepa's new drug marketing application in mainland China

References:

[1] Eddingpharm Receives New Drug Approval for VASCEPA® in Hong Kong, China to Reduce Risk of Cardiovascular Events.

Note: The original text has been deleted